ALS genetic screening study for new treatments
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study screens people with ALS to see if they might qualify for future gene-targeted treatments. It helps match you to trials that may be a good fit for your genetic type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with ALS (possible, probable, or definite).
- Your muscle weakness from ALS started within the last 24 months.
- You have had or are getting a genetic test for ALS.
- Your breathing is at least 65% of normal for your age, height, and gender.
- You have not had a gene therapy for ALS before.
- You are not on permanent assisted ventilation (using a breathing machine more than 22 hours a day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic risk for amyotrophic lateral sclerosis (ALS) in families. It may help researchers understand who carries ALS-related gene changes and how that affects future care.
This study is looking for biological markers in the blood that can help monitor how ALS progresses and potentially detect it earlier. By participating, you may help improve future diagnosis and care for ALS patients.
This study tests whether a new treatment using special motor neuron cells made from stem cells (iPSCs) can help people with ALS. The cells will be transplanted into the spinal cord to try to slow the disease and improve function.
This study looks at people with amyotrophic lateral sclerosis (ALS), people who might have ALS, and also people related to someone with ALS. It may help researchers better understand ALS and related “motor neuron” conditions, and it involves participation that may include blood tests.
This study follows healthy people from families with a known ALS-causing gene mutation to look for early body or brain changes before symptoms begin. It may help researchers find ways to predict ALS risk earlier so future treatments can start sooner.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
Hear when a new ALS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.